BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Aging
Alzheimer's disease
Artificial intelligence
Biosimilars
China CAR T
Coronavirus
Infographics: Dynamic digital data analysis
Israel
IVDs on the rise
Radiopharmaceuticals
Rise of obesity
Top Biopharma Trends of 2023
Top Med-tech Trends of 2023
Top Preclinical Trends of 2023
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Sunday, June 30, 2024
Breaking News: Try BioWorld for free for two weeks
See today's BioWorld Science
Home
» First-in-class thioacrylamide compound reduces hepatic fibrosis in 3D spheroid MASH model
X
Upgrade your daily dose of biopharma and medtech news
Subscribe to BioWorld™ news services
See subscription options
To read the full story,
subscribe
or
sign in
.
Endocrine/metabolic
First-in-class thioacrylamide compound reduces hepatic fibrosis in 3D spheroid MASH model
June 14, 2024
No Comments
Investigators from CMR Curediab Metabolic Research GmbH recently disclosed preclinical data for a novel hepatoprotective thioacrylamide compound, HK-3, being developed for the treatment of metabolic dysfunction-associated steatohepatitis (MASH).
BioWorld Science
Conferences
International Liver Congress
Endocrine/metabolic